Journal of Hepatology最新文献

{"title":"Erratum to: ‘Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis’ [J Hepatol (2024) 80:268-281]","authors":"Ahmed Ghallab, Daniela González, Ellen Strängberg, Ute Hofmann, Maiju Myllys, Reham Hassan, Zaynab Hobloss, Lisa Brackhagen, Brigitte Begher-Tibbe, Julia C. Duda, Carolin Drenda, Franziska Kappenberg, Joerg Reinders, Adrian Friebel, Mihael Vucur, Monika Turajski, Abdel-latief Seddek, Tahany Abbas, Noha Abdelmageed, Samy A.F. Morad, Jan G. Hengstler","doi":"10.1016/j.jhep.2025.02.031","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.02.031","url":null,"abstract":"In this article, owing to a typesetter error, the supplementary video files were incorrectly named. This has now been updated online. The publisher apologises for any inconvenience caused.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"24 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EASL-ERN Clinical Practice Guidelines on Wilson’s disease","authors":"European Association for the Study of the Liver","doi":"10.1016/j.jhep.2024.11.007","DOIUrl":"10.1016/j.jhep.2024.11.007","url":null,"abstract":"<div><div>Wilson’s disease is an autosomal recessive disorder of copper metabolism which affects the liver, brain and other organs. Diagnosis is based on: clinical features; biochemical tests, including plasma ceruloplasmin concentration, 24-h urinary copper excretion, copper content in the liver; and molecular analysis. Leipzig score and additionally relative exchangeable copper determination are recommended for diagnosis. Pharmacological therapy comprises chelating agents (penicillamine, trientine) and zinc salts, while only chelators are recommended for significant liver disease. Monitoring is based on clinical symptoms, liver tests and copper metabolism (urinary copper excretion, exchangeable copper) to detect poor compliance and over/under-treatment. Acute liver failure is challenging as making a diagnosis is difficult and pharmacological therapy may not be sufficient to save life. Liver transplantation has a well-defined role in Wilsonian acute hepatic failure but may also be considered in neurological disease.</div></div>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 4","pages":"Pages 690-728"},"PeriodicalIF":26.8,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Register now for the EASL Congress 2025, 7-10 May in Amsterdam!","authors":"","doi":"10.1016/S0168-8278(25)00103-5","DOIUrl":"10.1016/S0168-8278(25)00103-5","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 4","pages":"Page iii"},"PeriodicalIF":26.8,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JHEP at a glance (April 2025)","authors":"","doi":"10.1016/S0168-8278(25)00128-X","DOIUrl":"10.1016/S0168-8278(25)00128-X","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 4","pages":"Pages e157-e167"},"PeriodicalIF":26.8,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Join the community and become an EASL member today!","authors":"","doi":"10.1016/S0168-8278(25)00105-9","DOIUrl":"10.1016/S0168-8278(25)00105-9","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 4","pages":"Page v"},"PeriodicalIF":26.8,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the Editor’s Desk…","authors":"Philip Newsome,&nbsp;Frank Tacke,&nbsp;Heiner Wedemeyer,&nbsp;Lorenza Rimassa,&nbsp;Annalisa Berzigotti,&nbsp;Tom H. Karlsen,&nbsp;Vlad Ratziu","doi":"10.1016/j.jhep.2025.01.037","DOIUrl":"10.1016/j.jhep.2025.01.037","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 4","pages":"Pages 549-552"},"PeriodicalIF":26.8,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Celebrate World Liver Day on 19 April! Read more and see how you can get involved.","authors":"","doi":"10.1016/S0168-8278(25)00102-3","DOIUrl":"10.1016/S0168-8278(25)00102-3","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 4","pages":"Page ii"},"PeriodicalIF":26.8,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The EASL Guidelines app is your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Download it now!","authors":"","doi":"10.1016/S0168-8278(25)00104-7","DOIUrl":"10.1016/S0168-8278(25)00104-7","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 4","pages":"Page iv"},"PeriodicalIF":26.8,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous liver transplant and sleeve gastrectomy provides durable weight loss, improves metabolic syndrome and reduces allograft steatosis","authors":"Ellen L. Larson, Samia D. Ellias, Daniel J. Blezek, Jason Klug, Robert P. Hartman, Nickie Francisco Ziller, Heather Bamlet, Shennen A. Mao, Dana K. Perry, Induja R. Nimma, Dilhana Badurdeen, Liu Yang, Michael D. Leise, Kymberly D. Watt, Tayyab S. Diwan, Timucin Taner, Charles D. Rosen, Enrique F. Elli, James A. Madura, Caroline C. Jadlowiec, Julie K. Heimbach","doi":"10.1016/j.jhep.2025.02.030","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.02.030","url":null,"abstract":"<h3>Background and Aims</h3>The prevalence of obesity and metabolic syndrome (MetS) is rising among liver transplant (LT) candidates, many of whom have Metabolic-Associated Steatotic Liver Disease (MASLD). Following LT, untreated obesity often causes recurrent MASLD. We treated patients with obesity with LT and concurrent sleeve gastrectomy (LTSG), aiming to determine long-term impact on obesity, MetS and recurrent MASLD after transplantation.<h3>Methods</h3>A multicenter retrospective cohort study analyzed patients undergoing LTSG using a single clinical protocol (n=72), and patients with BMI &gt;30 who underwent LT alone for MASLD (n=185). Follow-up duration was 4-153 (median 41) months for LTSG and 12-161 (median 75) months for LT. Outcomes included mortality, graft loss, BMI, MetS components, allograft steatosis and fibrosis.<h3>Results</h3>Mortality and graft loss were not significantly different between LT and LTSG patients. Post-LTSG patients had significantly lower prevalence of diabetes for &gt;8 years (<em>p</em>&lt;0.05); hypertension decreased from 61.1% to 35.8% (<em>p</em>&lt;0.01). LTSG patients, with average starting BMI of 45.5, had significant weight loss compared to baseline for &gt;9 years (<em>p</em>&lt;0.001). LT-alone patients, average starting BMI 34.0, experienced no significant change in BMI or diabetes. Development of allograft steatosis was significantly lower in LTSG vs LT patients (<em>p</em>=0.004). Fibrosis prevalence was reduced in LTSG vs LT patients 3-10 years postoperatively; although not statically significant, relative risk ratio was 0.46 (<em>p</em>=0.09). One LTSG patient had a gastric sleeve leak; one required hiatal hernia repair. Severe GERD occurred in 11.1% of LTSG patients; risk factors included pre-existing diabetes and GERD.<h3>Conclusions</h3>LTSG results in sustained weight loss, resolution of diabetes and hypertension, and reduced recurrence of steatosis and possibly fibrosis compared to LT alone. It confers no increase in mortality or graft loss.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"156 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic effects and mechanism of action of the pan PPAR agonist Lanifibranor","authors":"Silvia Sabatini, Amalia Gastaldelli","doi":"10.1016/j.jhep.2025.03.003","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.03.003","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Conflict of interest</h2>AG reports consultancy/advisory boards fee for Boehringer Ingelheim, Eli Lilly and Company, Merck Sharp &amp; Dohme, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals; received lecture fees from Merck Sharp &amp; Dohme, Novo Nordisk, Eli Lilly and Company. SS reports no conflicts of interests related to this manuscript.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Authors’ contributions</h2>S.S and A.G. equally contributed to the writing of the manuscript.Lanifibranor is a triple peroxisome proliferator-activated receptor (PPAR) agonist and is one of the new molecules under investigation for the treatment of MASH with significant fibrosis (F2/F3. Results from the Phase 2b NATIVE trial [1] showed a significant reduction of at least 2 SAF-A score points without worsening of fibrosis (primary endpoint) in 55% and 48% of patients treated with the once-daily doses of 1200 mg and 800</section></section><section><section><h2>Financial support</h2>Internal funds of the Institute of Clinical Physiology-CNR.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"32 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}